Renalytix (NASDAQ:RNLX) Trading Up 5.7% – Still a Buy?

Shares of Renalytix Plc (NASDAQ:RNLX) were up 5.7% on Wednesday . The company traded as high as $0.23 and last traded at $0.21. Approximately 934,400 shares changed hands during trading, a decline of 36% from the average daily volume of 1,451,440 shares. The stock had previously closed at $0.20.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Renalytix in a research note on Friday, July 12th.

Renalytix Stock Performance

The company has a market capitalization of $17.18 million, a P/E ratio of -0.53 and a beta of 2.72. The company’s fifty day simple moving average is $0.28 and its 200-day simple moving average is $0.43.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Renalytix stock. Levin Capital Strategies L.P. purchased a new position in Renalytix Plc (NASDAQ:RNLX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 555,000 shares of the company’s stock, valued at approximately $128,000. Levin Capital Strategies L.P. owned about 0.72% of Renalytix at the end of the most recent quarter. Institutional investors own 9.92% of the company’s stock.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.